|Date||Rating||Target Price||Recommendation Price||Broker house|
|3 May 2011||2/5||--||--||CARE Report|
unijules life sciences ipo (CARE) CARE IPO GRADE
The grading is constrained by the small size of ULL's operations, pending litigations against the company, seasonal and volatile nature of raw materials, competition from established players in the industry and project risk on account of debt-funded expansion undertaken by the company. However, the grading derives strength from the promoters' experience, diversified product profile spread across allopathic and herbal formulations, moderate financial risk profile characterised by consistent growth in sales and profitability, stable margins and moderate capital structure. On a total operating income of Rs.198.28 crore in FY10, ULL reported PAT of Rs.12.62 crore. As per unaudited H1FY11 results, ULL reported total operating income of Rs.93.83 crore and PAT of Rs.6.49 crore.